Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enhancing malignant melanoma immunological engagement using sequential therapy with ipilimumab and electrochemotherapy
2014-004420-22Phase 4Terminated
- Sponsor
- University College Cork
- Start
- Jan 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ipilimumab in melanoma, sponsored by University College Cork. Primary endpoint: Primary safety and tolerability. Started Jan 2015; status: terminated.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2014-004420-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004420-22.